Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed

BACKGROUND: Malignant mesothelioma is a cancer which is refractory to current treatments. Imatinib mesylate is a selective inhibitor of tyrosine kinases such as bcr‐abl, c‐Kit, c‐Fms and platelet derived growth factor receptor β (PDGFRβ). PDGFRβ is often overexpressed in mesothelioma cells and is a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Bertino, Pietro, Porta, Camillo, Barbone, Dario, Germano, Serena, Busacca, Sara, Pinato, Sabrina, Tassi, Giancarlo, Favoni, Roberto, Gaudino, Giovanni, Mutti, Luciano
Format: Artigo
Idioma:Inglês
Publicat: BMJ Group 2007
Matèries:
Lung Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2117287/
https://ncbi.nlm.nih.gov/pubmed/17311837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thx.2006.069872
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars